Australia - angielski - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sitagliptin phosphate monohydrate -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sitagliptin phosphate monohydrate -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - sitagliptin phosphate monohydrate -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium stearylfumarate; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin pcor is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - angielski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 113.373 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; hyprolose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin.,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)

Australia - angielski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 56.686 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin.,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)

Australia - angielski - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sitagliptin hydrochloride monohydrate, quantity: 28.343 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: hyprolose; calcium hydrogen phosphate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin lupin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,? monotherapy when metformin is considered inappropriate due to intolerance; or,? in combination with other antihyperglycaemic agents, including insulin,(see section 5.1 pharmacodynamic properties - clinical trials and section 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies.)

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 128.5mg equivalent to 100 mg sitagliptin - film coated tablet - 100 mg - active: sitagliptin phosphate monohydrate 128.5mg equivalent to 100 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 32.125mg equivalent to 25 mg sitagliptin - film coated tablet - 25 mg - active: sitagliptin phosphate monohydrate 32.125mg equivalent to 25 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

apotex nz ltd - sitagliptin phosphate monohydrate 64.25mg equivalent to 50 mg sitagliptin - film coated tablet - 50 mg - active: sitagliptin phosphate monohydrate 64.25mg equivalent to 50 mg sitagliptin excipient: calcium hydrogen phosphate croscarmellose sodium hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate   microcrystalline cellulose purified talc titanium dioxide - monotherapy: sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus. combination with metformin: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when diet and exercise, plus the single agent do not provide adequate glycaemic control. combination with a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a ppar-gamma agonist (i.e. thiazolidinediones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a sulfonylurea: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with metformin and a ppar-gamma agonist: sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a ppar-gamma agonist (i.e. thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycaemic control. combination with insulin: sitagliptin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin (with or without metformin).